← ANALYST RATINGS · TIPRANKS
Benitec Biopharma (BNTC): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $24.67, the highest $32.00, the lowest $17.00. The average is +204.2% from the last price of $8.11.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $8.00−5.9% | Hold | −1.4% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Sell | −7.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 → $8.00−5.9% | Hold | −1.4% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.00 → $8.00−11.1% | Hold | −1.4% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.00 → $8.00−11.1% | Hold | −1.4% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.50 → $8.00−5.9% | Hold | −1.4% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $32.00 | Buy | +294.6% | Reiterated | 06.10.26on TipRanks 06:55 | −3.0%next day +0.1% · 5 days −4.0% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $17.00 | Buy | +109.6% | Reiterated | 05.10.26on TipRanks 14:25 | +2.1%next day −3.0% · 5 days −2.2% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 03:20 | −8.1%next day +0.4% · 5 days −3.3% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $25.00 | Buy | +208.3% | Reiterated | 15.09.26on TipRanks 09:35 | −8.1%next day +0.4% · 5 days −3.3% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | — | Hold | — | Downgrade | 10.06.26on TipRanks 07:00 | −2.3%next day +4.7% · 5 days +11.4% | ↗ |
| Unknown Analyst | Leerink Partners | $18.00 | Buy | +121.9% | Reiterated | 15.05.26on TipRanks May 22 21:06 | −1.8%next day −5.2% · 5 days −3.1% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | $20.00 → $22.00+10.0% | Buy | +171.3% | Reiterated | 04.11.25on TipRanks 06:55 | +0.2%next day +0.1% · 5 days −16.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Benitec Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.67 at a price of $10.00 (+146.7%); now: $24.67 at $8.11 (+204.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 0 | 3 | 5 |
| Buy | 1 | 1 | 2 | 1 | 2 | 1 |
| Hold | 1 | 2 | 2 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q1 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.27 (from $-0.30 to $-0.20). Last quarter: $-0.26.
Best top-analyst consensus in the sector · Healthcare
About Benitec Biopharma
- CEO: Jerel A. Banks
- Employees: 24
- 3940 Trust Way, Hayward, CA, 94545, US
- benitec.com
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Data from the stock’s TipRanks forecast page, read 143 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗